The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Arming antibodies: prospects and challenges for immunoconjugates
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Self-citationDevelopment of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Self-citationFrancisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Self-citationApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Cited by
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
Sletten, E. M., & Bertozzi, C. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900942 · Cited by 3,165
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
Kobayashi, H., Ogawa, M., Alford, R., Choyke, P. L., & Urano, Y. (2010) · Chemical Reviews · doi:10.1021/cr900263j · Cited by 2,200
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,032
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Tetrazine-Based Cycloadditions: Application to Pretargeted Live Cell Imaging
Devaraj, N. K., Weissleder, R., & Hilderbrand, S. A. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8004446 · Cited by 858
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Zhou, B.-B. S., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., & Dirks, P. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2137 · Cited by 841
Strategies for the intracellular delivery of nanoparticles
Chou, L. Y. T., Ming, K., & Chan, W. C. W. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00003e · Cited by 811
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes
Urano, Y., Asanuma, D., Hama, Y., Koyama, Y., Barrett, T., Kamiya, M., Nagano, T., Watanabe, T., Hasegawa, A., Choyke, P. L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1854 · Cited by 801
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Self-citationSite-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211023109 · Cited by 596
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Bioorthogonale Chemie – oder: in einem Meer aus Funktionalität nach Selektivität fischen
Sletten, E. M., & Bertozzi, C. R. (2009) · Angewandte Chemie · doi:10.1002/ange.200900942 · Cited by 564
Self-Cross-Linked Polymer Nanogels: A Versatile Nanoscopic Drug Delivery Platform
Ryu, J.-H., Chacko, R. T., Jiwpanich, S., Bickerton, S., Babu, R. P., & Thayumanavan, S. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1069932 · Cited by 553
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 520
Multimodality Molecular Imaging of Tumor Angiogenesis
Cai, W., & Chen, X. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045922 · Cited by 494
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Beyond the margins: real-time detection of cancer using targeted fluorophores
Zhang, R. R., Schroeder, A. B., Grudzinski, J. J., Rosenthal, E. L., Warram, J. M., Pinchuk, A. N., Eliceiri, K. W., Kuo, J. S., & Weichert, J. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.212 · Cited by 485
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Self-citationNucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives
Li, L., Xu, S., Yan, H., Li, X., Yazd, H. S., Li, X., Huang, T., Cui, C., Jiang, J., & Tan, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202003563 · Cited by 432
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Self-citationPET imaging with 89Zr: From radiochemistry to the clinic
Deri, M. A., Zeglis, B. M., Francesconi, L. C., & Lewis, J. S. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.08.004 · Cited by 423
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Self-citationKobayashi, H., & Choyke, P. L. (2011) · Accounts of Chemical Research · doi:10.1021/ar1000633 · Cited by 416
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Self-citationMonoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Self-citationAnalytical methods for physicochemical characterization of antibody drug conjugates
Wakankar, A., Chen, Y., Gokarn, Y., & Jacobson, F. S. (2011) · mAbs · doi:10.4161/mabs.3.2.14960 · Cited by 382
Devaraj, N. K., Upadhyay, R., Haun, J. B., Hilderbrand, S. A., & Weissleder, R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903233 · Cited by 378
Formulation and delivery issues for monoclonal antibody therapeutics
Daugherty, A. L., & Mrsny, R. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.011 · Cited by 351
Biosynthesis and function of polyacetylenes and allied natural products
Minto, R. E., & Blacklock, B. J. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.02.002 · Cited by 351
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
A general approach to site-specific antibody drug conjugates
Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H., Sun, Y., Phuong, T., Barnett, R., Hehli, B., Song, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321237111 · Cited by 319
Protein Organic Chemistry and Applications for Labeling and Engineering in Live‐Cell Systems
Takaoka, Y., Ojida, A., & Hamachi, I. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201207089 · Cited by 314
Anticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
Badescu, G., Bryant, P., Bird, M., Henseleit, K., Swierkosz, J., Parekh, V., Tommasi, R., Pawlisz, E., Jurlewicz, K., Farys, M., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500148x · Cited by 290
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040561 · Cited by 285
Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells
Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4583 · Cited by 284
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Smart Injectable Hydrogels for Cancer Immunotherapy
Chao, Y., Chen, Q., & Liu, Z. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201902785 · Cited by 271
Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions
Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., & Kiessling, L. L. (2007) · ACS Chemical Biology · doi:10.1021/cb6003788 · Cited by 270
Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris III, H. A., LoRusso, P. M., Yi, J.-H., Saad, O., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1817-3 · Cited by 262
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
DARPins: A new generation of protein therapeutics
Stumpp, M. T., Binz, H. K., & Amstutz, P. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.013 · Cited by 254
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
RosettaAntibodyDesign (RAbD): a general framework for computational antibody design
Adolf-Bryfogle, J., Kalyuzhniy, O., Kubitz, M., Weitzner, B. D., Hu, X., Adachi, Y., Schief, W. R., & Dunbrack, R. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006112 · Cited by 227
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209
Killing cancer cells by targeted drug-carrying phage nanomedicines
Bar, H., Yacoby, I., & Benhar, I. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-37 · Cited by 149
Ahn, J., Miura, Y., Yamada, N., Chida, T., Liu, X., Kim, A., Sato, R., Tsumura, R., Koga, Y., Yasunaga, M., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.069 · Cited by 147
“Consequently, the drugs conjugated to the antibody must be highly cytotoxic, such as auristatins [8,9], maytansines [10,11] and calicheamicins [12], which are 100e1000 times higher than typical anticancer drugs, for exerting enough efficacy, although there are growing concerns over side effects from decomposition of A…”
BackgroundGalsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145
Nessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., Abu-Yousif, A. O., Sandal, T., Legg, J., Thompson, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2295 · Cited by 128
Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Wang, S., Placzek, W. J., Stebbins, J. L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E. B., & Pellecchia, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201743s · Cited by 94
Zhong, Q., Bielski, E. R., Rodrigues, L. S., Brown, M. R., Reineke, J. J., & da Rocha, S. R. P. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00126 · Cited by 88
Polymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
Lutterbuese, R., Raum, T., Kischel, R., Lutterbuese, P., Schlereth, B., Schaller, E., Mangold, S., Rau, D., Meier, P., Kiener, P. A., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819b7c70 · Cited by 77
“To increase potency, many approaches have been developed over the past 20 years, including conjugation of antibodies with bacterial and plant toxins, chemotherapeutics, radioisotopes, inflammatory cytokines, RNAses, and enzymes that convert prodrugs.(2) So far, market approval has only been achieved with 1 immunotoxin…”
BackgroundMinor groove binder antibody conjugates employing a water soluble β-glucuronide linker
Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., & Senter, P. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.071 · Cited by 59
Self-citation
Metadata
- Authors
- Wu, A. M., & Senter, P. D.
- Venue
- Nature Biotechnology
- Published
- 2005-09-01
- Volume
- 23
- Issue
- 9
- Pages
- 1137-1146
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2048313558
- Cited by
- 1,052
- References
- 74
- FWCI
- 53.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.